SARS-CoV-2 viral spike protein binds to the membrane-bound form of angiotensin-converting enzyme 2 (ACE2) to infect the host cell. For this reason, we carried out a docking study to determine if ivermectin might be able to attach to the SARS-CoV-2 spike receptor-binding domain bound with ACE2. [...] The ivermectin docking site we identified, between the viral spike and the ACE2 receptor, may interfere with the attachment of the spike to the human cell membrane.